Tiziana to Participate in January Investor Meetings
New York, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough CNS immunomodulation approaches to enhance the functionality of Treg-based therapies, announced today that the Company plans to present at the Biotech Showcase and host institutional investor and partnering meetings at this event, as well as at the LifeSci Corporate Access Event. Both in-person events are taking place January 9-10, 2023 in San Francisco, California.
LifeSci Partners Corporate Access Event:
Dr. Matthew Davis, Chief Medical Officer and acting Chief Scientific Officer and the Tiziana team, will be hosting 1x1 institutional investor meetings.
Date/Time: Monday, January 9, 2023
Location: Beacon Grand Hotel in San Francisco
Please click to register for the conference and schedule a meeting with management via the online system managed by LifeSci Partners,.
Biotech Showcase:
Dr. Matthew Davis, Chief Medical Officer and acting Chief Scientific Officer and the Tiziana team, will give a corporate presentation and host 1x1 institutional investor and partnering meetings.
Date/Time: Tuesday January 10, 2023, at 11:00 am PT
Location: Hilton San Francisco Union Square in San Francisco
To schedule a meeting with management, investors can register on the Biotech Showcase
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough immunomodulation therapies via novel routes of drug delivery. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Hana Malik, Business Development, and Investor Relations Manager
+44 (0) 207 495 2379
email:
Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
